Measuring Outcome After Stroke: More Lessons Learned Again.
作者信息
Lyden Patrick D
机构信息
From the Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA.
出版信息
Stroke. 2020 Apr;51(4):1053-1054. doi: 10.1161/STROKEAHA.119.028214. Epub 2020 Feb 27.
Abstract
摘要
相似文献
1
Measuring Outcome After Stroke: More Lessons Learned Again.卒中后结局的测量：再次吸取的更多经验教训。
Stroke. 2020 Apr;51(4):1053-1054. doi: 10.1161/STROKEAHA.119.028214. Epub 2020 Feb 27.
2
Stroke Treatment With Intravenous Tissue-Type Plasminogen Activator: More Proof That Time Is Brain.静脉注射组织型纤溶酶原激活剂治疗中风：进一步证明时间就是大脑。
Circulation. 2017 Jan 10;135(2):140-142. doi: 10.1161/CIRCULATIONAHA.116.025724.
3
Time Is Brain.
Stroke. 2019 Mar;50(3):552-553. doi: 10.1161/STROKEAHA.118.024214.
4
Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.接受不同剂量重组组织型纤溶酶原激活剂的中风患者的治疗结果。
Drug Des Devel Ther. 2017 May 18;11:1559-1566. doi: 10.2147/DDDT.S133759. eCollection 2017.
5
Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.急性缺血性卒中的静脉滴注联合血管内取栓溶栓治疗
J Stroke Cerebrovasc Dis. 2018 Jan;27(1):61-67. doi: 10.1016/j.jstrokecerebrovasdis.2017.07.033. Epub 2017 Sep 1.
6
Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus.
Med J Aust. 2005 Jan 3;182(1):44-5; author reply 45.
7
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.使用idarucizumab逆转达比加群后，重组组织型纤溶酶原激活剂成功治疗缺血性中风：一例报告。
J Med Case Rep. 2019 Dec 26;13(1):390. doi: 10.1186/s13256-019-2326-y.
8
Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus.急性缺血性卒中中的组织型纤溶酶原激活剂（tPA）：开展学术交流并达成共识的时候了。
Med J Aust. 2005 Jan 3;182(1):45; author reply 45.
9
Telemedicine in Prehospital Acute Stroke Care: An Expanding Infrastructure for Treatment and Research.远程医疗在院前急性脑卒中救治中的应用：治疗和研究的扩展基础设施。
J Am Heart Assoc. 2019 Mar 19;8(6):e012259. doi: 10.1161/JAHA.119.012259.
10
ECASS: lessons for future thrombolytic stroke trials. European Cooperative Acute Stroke Study.
JAMA. 1995 Oct 4;274(13):1058-9.
引用本文的文献
1
Stroke survivors' preferences on assessing patient-reported outcome measures.脑卒中幸存者对评估患者报告结局测量的偏好。
J Patient Rep Outcomes. 2023 Nov 30;7(1):124. doi: 10.1186/s41687-023-00660-1.
2
The 100 most-cited articles about the role of neurovascular unit in stroke 2001-2020: A bibliometric analysis.2001-2020 年关于神经血管单元在中风中作用的 100 篇最具引用价值的文章：文献计量分析。
CNS Neurosci Ther. 2021 Jul;27(7):743-752. doi: 10.1111/cns.13636. Epub 2021 Mar 25.
本文引用的文献
1
Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo.重新定义的早期神经功能改善测量指标显示阿替普酶治疗优于安慰剂。
Stroke. 2020 Apr;51(4):1226-1230. doi: 10.1161/STROKEAHA.119.027476. Epub 2020 Feb 27.
2
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.阿替普酶治疗急性卒中对功能结局分布的影响：9项试验的汇总分析
Stroke. 2016 Sep;47(9):2373-9. doi: 10.1161/STROKEAHA.116.013644. Epub 2016 Aug 9.
3
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.在国立神经疾病与中风研究所组织型纤溶酶原激活剂（tPA）中风试验中寻找衡量组织型纤溶酶原激活剂有效性的最有力指标。
Stroke. 2000 Oct;31(10):2335-41. doi: 10.1161/01.str.31.10.2335.
4
Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight.
Ann Emerg Med. 1997 Nov;30(5):676-82. doi: 10.1016/s0196-0644(97)99996-0.
5
Tissue plasminogen activator for acute ischemic stroke.用于急性缺血性卒中的组织型纤溶酶原激活剂
N Engl J Med. 1995 Dec 14;333(24):1581-7. doi: 10.1056/NEJM199512143332401.
6
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.中风的紧急治疗。第二部分。发病91 - 180分钟后给予组织纤溶酶原激活剂的初步研究。
Stroke. 1992 May;23(5):641-5. doi: 10.1161/01.str.23.5.641.
7
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.
Stroke. 1992 May;23(5):632-40. doi: 10.1161/01.str.23.5.632.
Zotero 插件